Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.39 |
| ▸ | WNT3A | P56704 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 3/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15441306 | 0.90 | FABP4 (0.39) | CTNNB1WNT3ACYP3A4FABP4NR1I2 | |
| SCHEMBL13269540 | 0.83 | CYP3A4 (0.43) | CTNNB1WNT3ACYP3A4FABP4NR1I2 | |
| SCHEMBL13193329 | 0.81 | CTNNB1 (0.37) | CTNNB1WNT3ACYP3A4FABP4NR1I2 | |
| SCHEMBL15441320 | 0.80 | PSIP1 (0.41) | CTNNB1WNT3ACYP3A4FABP4NR1I2 | |
| SCHEMBL15441495 | 0.79 | CTNNB1 (0.37) | CTNNB1WNT3ACYP3A4FABP4SLC6A9 | |
| SCHEMBL13465224 | 0.79 | CYP3A4 (0.41) | CTNNB1WNT3ACYP3A4FABP4NR1I2 | |
| SCHEMBL13465471 | 0.79 | FABP4 (0.43) | CTNNB1WNT3ACYP3A4FABP4NR1I2 | |
| SCHEMBL15441423 | 0.79 | CYP3A4 (0.43) | CTNNB1WNT3ACYP3A4FABP4NR1I2 | |
| SCHEMBL13269068 | 0.77 | CYP3A4 (0.39) | CTNNB1WNT3ACYP3A4FABP4NR1I2 | |
| SCHEMBL13465458 | 0.77 | PSIP1 (0.36) | CTNNB1WNT3ACYP3A4FABP4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604900-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-03-28 | — | — | US | disclosed |
| US-9604900-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-03-28 | — | — | US | disclosed |
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | POLRMT, MAVS, EIF2AK2 | CTNNB1 3907/4885WNT3A 3567/4885CYP3A4 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.